On Mar. 5, 2020, Heat Biologics announced a strategic collaboration with the University of Miami Miller School of Medicine to support the development of a vaccine leveraging Heat’s proprietary gp96 platform designed to target the SARS-CoV-2 coronavirus that causes COVID-19.

Clinical and preclinical studies suggested that Heat’s gp96-based vaccines may be utilized to target COVID-19. Heat has treated more than 300 patients to date with its gp96-based therapeutic vaccines.